» Articles » PMID: 8013262

Osteopenia Associated with Non-insulin-dependent Diabetes Mellitus: What Are the Causes?

Overview
Specialty Endocrinology
Date 1994 Feb 1
PMID 8013262
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

This study investigated whether alterations in bone mineral content (BMC) and/or in the phosphate-calcium metabolism exist in non-insulin-dependent diabetes mellitus (NIDDM); whether they are linked to glycaemic control and whether antidiabetic therapy--oral agents or insulin--influences BMC and mineral metabolism. A cross-section assessment compared BMC and mineral metabolism in 60 well-controlled and 50 poorly controlled diabetic patients under oral hypoglycaemic therapy with 50 healthy controls. A longitudinal assessment improved the high glucose levels of the poorly controlled diabetic group either by increasing oral treatment or by adding a bedtime NPH insulin. Glycaemic control, BMC and mineral metabolism were followed-up for 1 year. In NIDDM patients BMC is reduced. This reduction is more marked in poorly controlled diabetic patients. In well-controlled diabetes osteocalcin levels are low. In poorly controlled patients glycosuria, hypercalcuria and parathyroid hyperactivity are present. In both groups vitamins 25(OH)-D, 1,25(OH)2-D and calcitonin levels are normal. Improving metabolic control increased BMC, normalized urinary calcium excretion and parathyroid activity and reduced osteocalcin levels. The type of anti-diabetic therapy does not have any significant effect upon BMC or upon phosphate-calcium metabolism. In conclusion, in NIDDM a hard-to-define osteoblast deficit appears to exist. In poorly controlled diabetes the loss of BMC is aggravated by the negative calcium balance caused by the renal calcium leak. This is due to glucosuric-induced osmotic diuresis and is maintained by parathyroid activation.

Citing Articles

Correlation between diabetes mellitus and refracture risk in patients with osteoporotic fractures: a retrospective cohort study.

Guo S, Xu J, Xu M, Li C, Gong Y, Lu K Aging Clin Exp Res. 2025; 37(1):85.

PMID: 40074983 PMC: 11903520. DOI: 10.1007/s40520-024-02917-1.


Diabetes and Osteoporosis.

Prasad T, Arjunan D, Pal R, Bhadada S Indian J Orthop. 2023; 57(Suppl 1):209-217.

PMID: 38107797 PMC: 10721588. DOI: 10.1007/s43465-023-01049-4.


Development and validation of a risk prediction model for osteoporosis in elderly patients with type 2 diabetes mellitus: a retrospective and multicenter study.

Tan J, Zhang Z, He Y, Xu X, Yang Y, Xu Q BMC Geriatr. 2023; 23(1):698.

PMID: 37891456 PMC: 10604807. DOI: 10.1186/s12877-023-04306-1.


Morroniside ameliorates glucocorticoid-induced osteoporosis and promotes osteoblastogenesis by interacting with sodium-glucose cotransporter 2.

Yang H, Dong R, Jia Y, Li Y, Luo G, Li T Pharm Biol. 2023; 61(1):416-426.

PMID: 36786302 PMC: 9930836. DOI: 10.1080/13880209.2023.2173787.


The Interplay Between Bone and Glucose Metabolism.

Cipriani C, Colangelo L, Santori R, Renella M, Mastrantonio M, Minisola S Front Endocrinol (Lausanne). 2020; 11:122.

PMID: 32265831 PMC: 7105593. DOI: 10.3389/fendo.2020.00122.